Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
Identifieur interne : 003302 ( Main/Curation ); précédent : 003301; suivant : 003303Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
Auteurs : Joseph H. Friedman [États-Unis] ; Robert M. Berman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stewart A. Factor [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; William H. Carson [États-Unis] ; Ronald N. Marcus [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antipsychotic, Antipsychotic Agents (therapeutic use), Aripiprazole, Delusion, Dose-Response Relationship, Drug, Drug Tolerance, Drug-Related Side Effects and Adverse Reactions, Female, Flexible, Hallucination, Human, Humans, Male, Middle Aged, Nervous system diseases, Parkinson Disease (complications), Parkinson disease, Parkinson's disease, Parkinson's psychosis, Pilot Projects, Piperazines (therapeutic use), Psychiatric Status Rating Scales, Psychosis, Psychotic Disorders (drug therapy), Psychotic Disorders (etiology), Quinolones (therapeutic use), Safety, Severity of Illness Index, Time Factors, aripiprazole, atypical antipsychotic drugs, delusions, drug‐induced psychosis in Parkinson's disease, hallucinations, secondary psychosis.
- MESH :
- chemical , therapeutic use : Antipsychotic Agents, Piperazines, Quinolones.
- complications : Parkinson Disease.
- drug therapy : Psychotic Disorders.
- etiology : Psychotic Disorders.
- Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Tolerance, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors.
Abstract
Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double‐blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open‐label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open‐label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21091
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002705
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002705
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001D61
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A68
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A68
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002B95
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001871
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001871
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001871
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004615
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001883
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001438
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001989
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004A84
Links to Exploration step
ISTEX:B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21091</idno>
<idno type="url">https://api.istex.fr/document/B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002705</idno>
<idno type="wicri:Area/Istex/Curation">002705</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D61</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17013906</idno>
<idno type="wicri:Area/PubMed/Corpus">002A68</idno>
<idno type="wicri:Area/PubMed/Curation">002A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B95</idno>
<idno type="wicri:Area/Ncbi/Merge">001871</idno>
<idno type="wicri:Area/Ncbi/Curation">001871</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001871</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:Area/Main/Merge">004615</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0090856</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001883</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001438</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001989</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:Area/Main/Merge">004A84</idno>
<idno type="wicri:Area/Main/Curation">003302</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University Medical School, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bristol Myers Squibb, Wallingford, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Rush University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otsuka America Pharmaceuticals, Inc., Princeton, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bristol Myers Squibb, Wallingford, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-12">2006-12</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2078">2078</biblScope>
<biblScope unit="page" to="2081">2081</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF</idno>
<idno type="DOI">10.1002/mds.21091</idno>
<idno type="ArticleID">MDS21091</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Aripiprazole</term>
<term>Delusion</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Tolerance</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Flexible</term>
<term>Hallucination</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Parkinson's psychosis</term>
<term>Pilot Projects</term>
<term>Piperazines (therapeutic use)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Psychosis</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (etiology)</term>
<term>Quinolones (therapeutic use)</term>
<term>Safety</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>aripiprazole</term>
<term>atypical antipsychotic drugs</term>
<term>delusions</term>
<term>drug‐induced psychosis in Parkinson's disease</term>
<term>hallucinations</term>
<term>secondary psychosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Piperazines</term>
<term>Quinolones</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Tolerance</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Psychiatric Status Rating Scales</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Aripiprazole</term>
<term>Délire</term>
<term>Flexible</term>
<term>Hallucination</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Psychose</term>
<term>Système nerveux pathologie</term>
<term>Sécurité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double‐blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open‐label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open‐label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2006:Friedman J:open:label:flexible"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson Disease and Movement Disorders Center, NeuroHealth</s1>
<s2>Warwick, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, Brown University Medical School</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Bristol Myers Squibb</s1>
<s2>Wallingford, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Rush University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Neurology, Indiana University</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
<affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Otsuka America Pharmaceuticals, Inc</s1>
<s2>Princeton, New Jersey</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Bristol Myers Squibb</s1>
<s2>Wallingford, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0090856</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 07-0090856 INIST</idno>
<idno type="RBID">Pascal:07-0090856</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001883</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001438</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001989</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:Area/Main/Merge">004A84</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson Disease and Movement Disorders Center, NeuroHealth</s1>
<s2>Warwick, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, Brown University Medical School</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Bristol Myers Squibb</s1>
<s2>Wallingford, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Rush University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Neurology, Indiana University</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
<affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Otsuka America Pharmaceuticals, Inc</s1>
<s2>Princeton, New Jersey</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Bristol Myers Squibb</s1>
<s2>Wallingford, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Aripiprazole</term>
<term>Delusion</term>
<term>Flexible</term>
<term>Hallucination</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Safety</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Psychose</term>
<term>Parkinson maladie</term>
<term>Hallucination</term>
<term>Délire</term>
<term>Flexible</term>
<term>Sécurité</term>
<term>Aripiprazole</term>
<term>Homme</term>
<term>Antipsychotique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21091</idno>
<idno type="url">https://api.istex.fr/document/B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002705</idno>
<idno type="wicri:Area/Istex/Curation">002705</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D61</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17013906</idno>
<idno type="wicri:Area/PubMed/Corpus">002A68</idno>
<idno type="wicri:Area/PubMed/Curation">002A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B95</idno>
<idno type="wicri:Area/Ncbi/Merge">001871</idno>
<idno type="wicri:Area/Ncbi/Curation">001871</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001871</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Friedman J:open:label:flexible</idno>
<idno type="wicri:Area/Main/Merge">004615</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease</title>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University Medical School, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berman, Robert M" sort="Berman, Robert M" uniqKey="Berman R" first="Robert M." last="Berman">Robert M. Berman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bristol Myers Squibb, Wallingford, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Rush University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carson, William H" sort="Carson, William H" uniqKey="Carson W" first="William H." last="Carson">William H. Carson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otsuka America Pharmaceuticals, Inc., Princeton, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcus, Ronald N" sort="Marcus, Ronald N" uniqKey="Marcus R" first="Ronald N." last="Marcus">Ronald N. Marcus</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Bristol Myers Squibb, Wallingford, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-12">2006-12</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2078">2078</biblScope>
<biblScope unit="page" to="2081">2081</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF</idno>
<idno type="DOI">10.1002/mds.21091</idno>
<idno type="ArticleID">MDS21091</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Tolerance</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson's disease</term>
<term>Parkinson's psychosis</term>
<term>Pilot Projects</term>
<term>Piperazines (therapeutic use)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (etiology)</term>
<term>Quinolones (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>aripiprazole</term>
<term>atypical antipsychotic drugs</term>
<term>delusions</term>
<term>drug‐induced psychosis in Parkinson's disease</term>
<term>hallucinations</term>
<term>secondary psychosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Piperazines</term>
<term>Quinolones</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Tolerance</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Psychiatric Status Rating Scales</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double‐blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open‐label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open‐label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:B4CD9A0DB5ADAB7A9A5761C7D6D569E1E6D105EF |texte= Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |